文献速递肝病

慢性肝病纤维化逆转:病理学家的视角

Fibrosis regression in chronic liver disease: The pathologist's view.
PubMed 文献 · J Hepatol · 2026-07-24

本综述指出,去除病因或有效治疗后显著肝纤维化可完全消失或大幅重塑,已建立的肝硬化逆转也有记录。现有半定量分期系统因分类性限制难以评估逆转,北京P-I-R分类仅在病毒性肝病中得到验证,逆转特征的临床意义尚待研究。作者呼吁肝病病理学界应对组织学评估不足和晚期纤维化「不可逆点」识别的挑战,或可借助人工智能辅助肝活检评估。

要点

  • 去除病因或有效治疗后显著肝纤维化可完全消失或大幅重塑,肝硬化逆转也有记录。
  • 半定量分期系统因分类性限制,难以精细评估纤维化逆转。
  • 北京P-I-R分类仅在病毒性肝病中验证,逆转特征的临床意义尚待研究。

核心结论

  • 肝纤维化逆转的组织学评估存在不足,需改进跨常见慢性肝病的评估体系并识别晚期纤维化的「不可逆点」。

研究设计与样本

  • 本文为简要综述,未报告系统检索范围或样本量。

主要发现

  • 众多观察表明去除启动因素或有效治疗后可出现显著肝纤维化完全消失或大幅重塑。
  • 已建立的肝硬化逆转也有文献记录。
  • 纤维化逆转研究多采用为评估进展性疾病开发的半定量分期系统,受分类性限制。
  • 北京P-I-R分类仅在病毒性肝病中得到验证。
  • 逆转特征的临床意义在很大程度上尚未被研究。

临床怎么用

  • 病理评估纤维化逆转时应认识半定量分期系统的分类性局限。
  • 北京P-I-R分类目前仅适用于病毒性肝病,不宜外推至其他慢性肝病。
  • 可探索人工智能辅助肝活检评估以应对纤维化逆转的组织学评估挑战。

局限性

  • 本文为简要综述,未报告系统检索策略或纳入研究数量。
  • 逆转特征的临床意义尚缺乏研究数据。
  • 北京P-I-R分类的验证仅限于病毒性肝病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Numerous observations have indicated that significant amounts of liver fibrosis can either completely disappear or be substantially remodelled after removal of the initiating agent or following effective therapeutic intervention. Reversal of established cirrhosis has also been documented. Studies of fibrosis regression have largely used semiquantitative staging systems that were developed to assess progressive disease and are limited by their categorical nature. A more nuanced system, the Beijing P-I-R classification, has been validated only in viral liver disease. The clinical significance of regressive features remains largely unstudied. In this brief review, we address shortcomings in (i) the histological assessment of fibrosis regression across the spectrum of common chronic liver diseases and (ii) the identification of a 'point of no return' in advanced fibrosis. We argue that the hepatopathology community should rise to these challenges, perhaps aided by the development of artificial intelligence solutions for the assessment of liver biopsies.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Burt AD, Behling C, Gouw ASH, et al. Fibrosis regression in chronic liver disease: The pathologist's view. J Hepatol. 2026. PMID: 42497924. doi:10.1016/j.jhep.2026.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。